Related Experiment Video

Updated: May 22, 2026

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
06:07

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors

Published on: August 5, 2022

Antiproliferative effects of DNA methyltransferase 3B depletion are not associated with DNA demethylation

Sabine Hagemann1, Dirk Kuck, Carlo Stresemann

  • 1Division of Epigenetics, DKFZ-ZMBH Alliance, German Cancer Research Center, Heidelberg, Germany.

Plos One
|May 8, 2012
PubMed

Insights

The de novo DNA methyltransferase 3B (DNMT3B) is not essential for maintaining aberrant DNA methylation in colon cancer. Reducing DNMT3B levels inhibited cancer cell proliferation but did not alter methylation patterns.

Area of Science:

  • Epigenetics
  • Cancer Biology
  • Molecular Oncology

Background:

  • Aberrant DNA methylation is a hallmark of cancer, contributing to gene silencing and tumor progression.
  • The de novo DNA methyltransferase 3B (DNMT3B) is implicated in establishing cancer-specific methylation patterns.
  • Previous research suggested DNMT3B depletion reactivates tumor suppressor genes, impacting cancer cell proliferation.

Purpose of the Study:

  • To investigate the role of DNMT3B in the establishment and maintenance of aberrant DNA methylation in human colon cancer cells.
  • To analyze genome-wide methylation changes following DNMT3B depletion.
  • To assess the antiproliferative effects of DNMT3B reduction in colon cancer.

Main Methods:

  • Utilized RNA interference to reduce DNMT3B protein levels in colon cancer cell lines.
  • Performed genome-scale DNA methylation profiling to detect alterations.
  • Quantified cancer cell proliferation rates.

Main Results:

  • Depletion of DNMT3B significantly reduced the proliferation rate of DNMT3B-overexpressing colon cancer cells.
  • Genome-wide methylation profiling did not reveal significant methylation changes at putative DNMT3B target genes.
  • DNMT3B was found to be dispensable for maintaining aberrant DNA methylation patterns in this context.

Conclusions:

  • DNMT3B is not required for the maintenance of aberrant DNA methylation in human colon cancer cells.
  • These findings challenge the direct role of DNMT3B in maintaining established cancer methylation patterns.
  • Implications for the development of targeted DNA methyltransferase inhibitors as epigenetic cancer therapeutics.

More Related Videos

Immunostaining for DNA Modifications: Computational Analysis of Confocal Images09:42

Immunostaining for DNA Modifications: Computational Analysis of Confocal Images

Published on: September 7, 2017

An Alternative Culture Method to Maintain Genomic Hypomethylation of Mouse Embryonic Stem Cells Using MEK Inhibitor PD0325901 and Vitamin C11:53

An Alternative Culture Method to Maintain Genomic Hypomethylation of Mouse Embryonic Stem Cells Using MEK Inhibitor PD0325901 and Vitamin C

Published on: June 1, 2018

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Epigenetic Regulation01:37

Epigenetic Regulation

Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
Phase II Reactions: Methylation Reactions01:17

Phase II Reactions: Methylation Reactions

Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...